



BIODIEM LTD  
ABN 20 096 845 993  
Suite 3, Level 11,  
470 Collins Street,  
Melbourne, Victoria, 3000  
Australia  
Phone: +613 9613 4100  
Web: www.biodiem.com

## ASX Announcement

### Proposed Delisting from ASX

Melbourne, 30 August 2013:

After careful consideration of various alternatives, the Board of BioDiem Limited (ASX:BDM) ("the Company" or "BioDiem") has determined to put a resolution to shareholders at its upcoming Annual General Meeting to delist the Company's securities from quotation on the ASX.

In summary, the reasons for the Company seeking shareholder approval to delist from ASX include:

- the effect that the perceived low market capitalisation of the Company has on commercial opportunities including out-licencing transactions (which are a core element of the Company's business);
- the disparity of sensitivity to positive announcements by the Company with the effect on the market price of the Company's securities;
- the general economic conditions and the effect those have on the Company's ability to raise capital; and
- the costs associated with the Company remaining listed on ASX where the Company and its shareholders receive only limited benefits from the Company remaining listed on ASX.

The ASX has provided the Company with its in-principle agreement to remove the Company from the official list of ASX pursuant to Listing Rule 17.11, on a date to be determined by the ASX. This agreement is subject to the following conditions:

1. That the request for removal of the Company from the official list of ASX is approved by ordinary resolution of ordinary shareholders of the Company;
2. A notice of general meeting seeking shareholder approval to request the removal of the Company from the official list of ASX must include a statement to the effect that the removal will take place no earlier than one month after the approval is granted; and
3. The Company must release the full terms of ASX's decision to the market immediately upon the Company's directors resolving to seek removal of the Company from the official list of ASX.

Further details relating to the reasons for the Company seeking to be delisted from ASX will be provided in the Company's Notice of Annual General Meeting and the Explanatory Statement accompanying that Notice of Annual General Meeting, expected to be issued by the Company in early September.

#### INDICATIVE DATES FOR THE DELISTING PROCESS (subject to ASX approval)

DATE	ACTION
6 September 2013	Announcement of AGM with NOM/Proxy to market via ASX
6 September 2013	NOM/Proxy Form dispatch to Shareholders
8 October 2013 – 12pm	Annual General Meeting
8 October 2013	Announcement of results of AGM released to market via ASX
9 November 2013	Delisting date from ASX (effective date of removal of the Company from the official list of ASX)

ENDS

**About BioDiem Ltd**

BioDiem (ASX: BDM) is an ASX-listed biopharmaceutical company developing vaccines and antimicrobials targeting treatment and prevention of infectious diseases and related cancers. The lead technology is the LAIV (Live Attenuated Influenza Virus) vaccine used for seasonal and pandemic influenza vaccines and is given intranasally. BDM-L, a therapeutic hepatitis vaccine project targeting hepatitis D and B is underway at the University of Canberra. BioDiem's antimicrobial, BDM-I, is in preclinical development for fungal and bacterial diseases. The SAVINE (scrambled antigen) technology is in development for tuberculosis and also EBV-related disease including nasopharyngeal cancer. BioDiem's retinal product, BDM-E, being developed for retinitis pigmentosa is available for outlicence.

For additional information, please visit [www.biodiem.com](http://www.biodiem.com)

**Contact****Investors**

Julie Phillips, Chief Executive Officer  
BioDiem Ltd  
Phone +61 3 9613 4100  
Email [jphillips@biodiem.com](mailto:jphillips@biodiem.com)

**Media**

Rebecca Wilson  
Buchan Consulting  
Phone +61 3 8866 1216 / +61 (0) 417 382 391  
Email [rwilson@buchanwe.com.au](mailto:rwilson@buchanwe.com.au)